Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
CGEM Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Cullinan Therapeutics, Inc.NASDAQ: CGEM
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital grows, but more slowly than its trailing trend
Q1 FY2026 change in working capital of $3.3M (cash outflow) rose 84.2% year over year, behind the +237.9% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +8.0% a year.
Context
- Change in working capital increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +84.2% toward the trailing-twelve-month pace of +237.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 14.08M USD
- Year-over-year change
- +3720.6%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.08M | +3720.6% |
| FY2024 | 2024-12-31 | (389K) | -14.7% |
| FY2023 | 2023-12-31 | (339K) | -103.0% |
| FY2022 | 2022-12-31 | 11.18M | +415.6% |
| FY2021 | 2021-12-31 | (3.54M) | — |
Change in Working Capital vs competitors
How CGEM compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +237.9% is the 2nd highest of 10, against a peer median of +67.2%.
- Over three fiscal years its annual growth of +8.0% compares with a peer median of -1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $301.51M USD | +166.3% | — | 22.2% | |
| LTM Aug 2026 | $50.82M USD | +271.7% | +18.4% | 7.2% | |
| LTM Mar 2026 | $17.87M USD | +67.2% | +66.6% | 11.4% | |
| LTM Mar 2026 | €14.05M EUR | -90.7% | — | 37.7% | |
| LTM Mar 2026 | $12.58M USD | +237.9% | +8.0% | — | |
| LTM Mar 2026 | $12.14M USD | +163.0% | +16.2% | 56.2% | |
| LTM Mar 2026 | $5.08M USD | +126.1% | -19.7% | 6.4% | |
| LTM Mar 2026 | $3.95M USD | +22.3% | -67.6% | — | |
| LTM Jun 2026 | $2.5M USD | -91.4% | -1.0% | 2.4% | |
| LTM Mar 2026 | $1.38M USD | -145.8% | -19.2% | — | |
| LTM Dec 2025 | $0 USD | — | -1.2% | 0.0% | |
| Peer median (excluding CGEM) | — | +67.2% | -1.1% | 9.3% | |
Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (67.49M) | 109.2M | (153.16M) | (167.58M) | (219.88M) |
| Depreciation & Amortization | 53K | 93K | 310K | 306K | 311K |
| Deferred Income Tax | 3.1M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.38M | 27.96M | 30.44M | 37.82M | 36.04M |
| Change in Working Capital | (3.54M) | 11.18M | (339K) | (389K) | 14.08M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.84M) | (509K) | (167K) | (812K) | (839K) |
| Other Working Capital | 1.29M | 11.69M | (172K) | 423K | 14.92M |
| Other Non-Cash Items | 67K | (275.09M) | (11.52M) | (15.47M) | (6.31M) |
| Operating Cash Flow | (43.43M) | (126.66M) | (134.28M) | (145.3M) | (175.75M) |
| Capital Expenditures | (589.23K) | (1.13M) | (208K) | 0 | (49K) |
| Acquisitions (Net) | 923K | 275M | (36.01K) | 0 | 0 |
| Purchases of Investments | (525.81M) | (377.92M) | (373.38M) | (721.13M) | (236.53M) |
| Sales of Investments | 192.04M | 352.93M | 409.4M | 584.82M | 416.57M |
| Other Investing Activities | (333.78K) | 91K | 36.01K | 0 | 0 |
| Investing Cash Flow | (333.78M) | 248.98M | 35.81M | (136.31M) | 179.99M |
| Debt Repayment | 0 | (2.2M) | 1.83M | 0 | 0 |
| Common Stock Issued | 267.27M | 8.4M | 38.39M | 262.65M | 1.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | (32.13M) | 538K | 3.54M | 0 |
| Financing Cash Flow | 268.78M | (25.93M) | 40.75M | 266.19M | 1.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (108.42M) | 96.38M | (57.72M) | (15.43M) | 5.33M |
| Free Cash Flow | (44.02M) | (127.8M) | (134.48M) | (145.3M) | (175.8M) |
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.